Original Publication Date: 25 January, 2014
Publication / Source: Lung Cancer Management
Authors: Takashi Ninomiya, Nagio Takigawa, Shinichi Toyooka, Katsuyuki Hotta, Mitsune Tanimoto & Katsuyuki Kiura
Activating EGFR mutations in non-small-cell lung cancer were discovered in 2004. Patients harboring these mutations, who have been treated with EGFR–tyrosine kinase inhibitor (TKI), are expected to live longer than 2 years. However, lung cancer eventually progresses and the patients die of the disease. Thus, alternative treatments are needed for EGFR-mutated lung cancer. Here, we review the alternative treatments for patients with activating EGFR mutation.